Moderna’s COVID-19 Vaccine Receives Approval for Emergency Use in Japan

 Moderna’s COVID-19 Vaccine Receives Approval for Emergency Use in Japan

Moderna’s COVID-19 Vaccine Receives Approval for Emergency Use in Japan

Shots:

  • MHLW has granted special approval under article 14-3 of the PMDA for emergency use of Moderna’s mRNA COVID-19 vaccine based on Takeda’s P-I/II immunogenicity and safety clinical trial
  • The interim analysis showed that binding Ab and neutralizing Ab titers were elevated @28days after the second dose in 100% of people vaccinated with two 0.5ml doses of TAK-919 given 28 days apart. The vaccine was well tolerated with no safety signals observed
  • The response is consistent with the results from Moderna’s pivotal P-III COVE trial conducted in the US. Takeda plans to begin distribution in Japan imminently

Click here to­ read full press release/ article | Ref: Takeda | Image: The Japan Times

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post